The Nephrotoxicity of Vancomycin

E J Filippone, W K Kraft, J L Farber, E J Filippone, W K Kraft, J L Farber

Abstract

Vancomycin use is often associated with nephrotoxicity. It remains uncertain, however, to what extent vancomycin is directly responsible, as numerous potential risk factors for acute kidney injury frequently coexist. Herein, we critically examine available data in adult patients pertinent to this question. We review the pharmacokinetics/pharmacodynamics of vancomycin metabolism. Efficacy and safety data are discussed. The pathophysiology of vancomycin nephrotoxicity is considered. Risk factors for nephrotoxicity are enumerated, including the potential synergistic nephrotoxicity of vancomycin and piperacillin-tazobactam. Suggestions for clinical practice and future research are given.

© 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

References

    1. Liu, C. , et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin‐resistant staphylococcus aureus infections in adults and children: Executive summary. Clin. Infect. Dis. 52, 285–292 (2011).
    1. Jeffres, M.N. , Isakow, W. , Doherty, J.A. , Micek, S.T. & Kollef, M.H. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care‐associated methicillin‐resistant staphylococcus aureus pneumonia. Clin. Ther. 29, 1107–1115 (2007).
    1. Sinha Ray, A. , Haikal, A. , Hammoud, K.A. & Yu, A.S.L. Vancomycin and the risk of AKI: A systematic review and meta‐analysis. Clin. J. Am. Soc. Nephrol. 11, 2132–2140 (2016).
    1. Cosgrove, S.E. et al. Initial low‐dose gentamicin for staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 48, 713–721 (2009).
    1. Carreno, J.J. , Kenney, R.M. , Divine, G. , Vazquez, J.A. & Davis, S.L. Randomized controlled trial to determine the efficacy of early switch from vancomycin to vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP‐NT). Ann. Pharmacother. 51, 185–193 (2017).
    1. Hazlewood, K.A. , Brouse, S.D. , Pitcher, W.D. & Hall, R.G. Vancomycin‐associated nephrotoxicity: grave concern or death by character assassination? Am. J. Med. 123, 182 (2010).e1–182.e7.
    1. Teng, C.B. et al. Continuation of high‐dose vancomycin despite nephrotoxicity. Antimicrob. Agents Chemother. 56, 3470–3471 (2012).
    1. Rybak, M. et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health‐System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66, 82 (2008).
    1. Georges, H. et al. Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 385–388 (1997).
    1. Larsson, A.J. , Walker, K.J. , Raddatz, J.K. & Rotschafer, J.C. The concentration‐independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother. 38, 589–597 (1996).
    1. Song, K.H. et al. Impact of area under the concentration‐time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin‐resistant staphylococcus aureus bacteraemia. Int. J. Antimicrob. Agents 46, 689–695 (2015).
    1. Men, P. , Li, H. , Zhai, S. & Zhao, R. Association between the AUC(0‐24)/MIC ratio of vancomycin and its clinical effectiveness: A systematic review and meta‐analysis. PLoS One 11, e0146224 (2015).
    1. Sader, H.S. , Rhomberg, P.R. & Jones, R.N. Nine‐hospital study comparing broth microdilution and etest method results for vancomycin and daptomycin against methicillin‐resistant staphylococcus aureus. Antimicrob. Agents Chemother. 53, 3162–3165 (2009).
    1. Hsu, D.I. et al. Comparison of method‐specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin‐resistant staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents. 32, 378–385 (2008).
    1. Tenover, F.C. & Moellering, R.C. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureus. Clin. Infect. Dis. 44, 1208–1215 (2007).
    1. Steinkraus, G. , White, R. & Friedrich, L. Vancomycin MIC creep in non‐vancomycin‐intermediate staphylococcus aureus (VISA), vancomycin‐susceptible clinical methicillin‐resistant S. aureus (MRSA) blood isolates from 2001‐05. J. Antimicrob. Chemother. 60, 788–794 (2007).
    1. van Hal, S.J. , Lodise, T.P. & Paterson, D.L. The clinical significance of vancomycin minimum inhibitory concentration in staphylococcus aureus infections: A systematic review and meta‐analysis. Clin. Infect. Dis. 54, 755–771 (2012).
    1. Mavros, M.N. et al. Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin‐susceptible staphylococcus aureus infections: a meta‐analysis and meta‐regression. Int. J. Antimicrob. Agents. 40, 496–509 (2012).
    1. Kalil, A.C. , Van Schooneveld, T.C. , Fey, P.D. & Rupp, M.E. Association between vancomycin minimum inhibitory concentration and mortality among patients with staphylococcus aureus bloodstream infections: a systematic review and meta‐analysis. JAMA 312, 1552–1564 (2014).
    1. Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(suppl. 1) (2006).
    1. Guidelines for the management of adults with hospital‐acquired, ventilator‐associated, and healthcare‐associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388–416 (2005).
    1. Ghosh, N. , Chavada, R. , Maley, M. , van Hal, S.J. Impact of source of infection and vancomycin AUC0‐24/MICBMD targets on treatment failure in patients with methicillin‐resistant staphylococcus aureus bacteraemia. Clin. Microbiol. Infect. 20, O1098–O1105 (2014).
    1. Neely, M.N. et al. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob. Agents Chemother. 58, 309–316 (2014).
    1. Hale, C.M. , Seabury, R.W. , Steele, J.M. , Darko, W. & Miller, C.D. Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC in patients with presumed MRSA infection? J. Pharm. Pract. <> (2016).
    1. Suzuki, Y. et al. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic‐pharmacodynamic analysis in patients with methicillin‐resistant Staphylococcus aureus pneumonia. Chemotherapy 58, 308–312 (2012).
    1. Steinmetz, T. , Eliakim‐Raz, N. , Goldberg, E. , Leibovici, L. & Yahav, D. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: A systematic review and meta‐analysis. Clin. Microbiol. Infect. 21, 665–673 (2015).
    1. Tongsai, S. & Koomanachai, P. The safety and efficacy of high versus low vancomycin trough levels in the treatment of patients with infections caused by methicillin‐resistant staphylococcus aureus: a meta‐analysis. BMC Res. Notes 9, 455 (2016).
    1. Barriere, S.L. , Stryjewski, M.E. , Corey, G.R. , Genter, F.C. & Rubinstein, E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus, A retrospective, post hoc, subgroup analysis of the phase 3 ATTAIN studies. BMC Infect. Dis. 14 (2014).
    1. Ye, Z. , Tang, H. & Zhai, S. Benefits of therapeutic drug monitoring of vancomycin. A systematic review and meta–analysis. PLoS One 8 (2013).
    1. Baptista, J.P. , Sousa, E. , Martins, P.J. & Pimentel, J.M. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int. J. Antimicrob. Agents. 39, 420–423 (2012).
    1. Kullar, R. et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy 31, 441–448 (2011).
    1. Avent, M.L. et al. Vancomycin therapeutics and monitoring: A contemporary approach. Intern. Med. J. 43, 110–119 (2013).
    1. Lodise, T.P. et al. Vancomycin exposure in patients with methicillin‐resistant staphylococcus aureus bloodstream infections: how much is enough? Clin. Infect. Dis. 59, 666–675 (2014).
    1. Pallotta, K.E. & Manley, H.J. Vancomycin use in patients requiring hemodialysis: a literature review. Semin. Dial. 21, 63–70 (2008).
    1. Decker, B.S. et al. Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clin. J. Am. Soc. Nephrology. 5, 1981–1987 (2010).
    1. DelDot, M.E. , Lipman, J. & Tett, S.E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol. 58, 259–268 (2004).
    1. Crew, P. , Heintz, S.J. & Heintz, B.H. Vancomycin dosing and monitoring for patients with end‐stage renal disease receiving intermittent hemodialysis. Am. J. Health Syst Pharm. 72, 1856–1864 (2015).
    1. Barth, R.H. & DeVincenzo, N. Use of vancomycin in high‐flux hemodialysis: experience with 130 courses of therapy. Kidney Int. 50, 929–936 (1996).
    1. Wold, J.S. & Turnipseed, S.A. Toxicology of vancomycin in laboratory animals. Rev. Infect. Dis. 3, S224–S229 (1981).
    1. King, D.W. & Smith, M.A. Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells. Toxicol. Vitro. 18, 797–803 (2004).
    1. Elyasi, S. , Khalili, H. , Hatamkhani, S. & Dashti‐Khavidaki, S. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur. J. Clin. Pharmacol. 69, 747–754 (2013).
    1. Nishino, Y. et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycin‐induced nephrotoxicity in rats. Free Radic. Res. 37, 373–379 (2003).
    1. Öktem, F. et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin‐induced nephrotoxicity: protection by erdosteine. Toxicology 215, 227–233 (2005).
    1. Celik, I. , Cihangiroglu, M. , Ilhan, N. , Akpolat, N. & Akbulut, H.H. Protective effects of different antioxidants and amrinone on vancomycin‐induced nephrotoxicity. Basic Clin. Pharmacol. Toxicol. 97, 325–332 (2005).
    1. Sakamoto, Y. et al. Vancomycin induces reactive oxygen species‐dependent apoptosis via mitochondrial cardiolipin peroxidation in renal tubular epithelial cells. Eur. J. Pharmacol. 800, 48–56 (2017).
    1. Hori, Y. et al. Megalin blockade with cilastatin suppresses drug‐induced nephrotoxicity. J. Am. Soc. Nephrol. 2017. doi: [Epub ahead of print].
    1. Luque, Y. et al. Vancomycin‐associated cast nephropathy. J. Am. Soc. Nephrol. 2017. doi: [Epub ahead of print].
    1. Horey, A. , Mergenhagen, K.A. & Mattappallil, A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis. Ann. Pharmacother. 46, 1477–1483 (2012).
    1. Davies, S.W. et al. Vancomycin‐associated nephrotoxicity: The obesity factor. Surg. Infect. 16, 684–693 (2015).
    1. Minejima, E. et al. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin‐treated patients. Antimicrob. Agents Chemother. 55, 3278–3283 (2011).
    1. Contreiras, C. et al. Identification of risk factors for nephrotoxicity in patients receiving extended‐duration, high‐trough vancomycin therapy. Can. J. Hosp. Pharm. 67, 126–132 (2014).
    1. Wong‐Beringer, A. , Joo, J. , Tse, E. & Beringer, P. Vancomycin‐associated nephrotoxicity: A critical appraisal of risk with high‐dose therapy. Int. J. Antimicrob. Agents. 37, 95–101 (2011).
    1. Malhotra, R. & Siew, E.D. Biomarkers for the early detection and prognosis of acute kidney injury. Clin. J. Am. Soc. Nephrol. 12, 149–173 (2017).
    1. Rhodes, N.J. et al. Evaluation of vancomycin exposures associated with elevations in novel urinary biomarkers of acute kidney injury in vancomycin‐treated rats. Antimicrob. Agents Chemother. 60, 5742–5751 (2016).
    1. Van Hal, S.J. , Paterson, D.L. & Lodise, T.P. Systematic review and meta‐analysis of vancomycin‐induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 57, 734–744 (2013).
    1. Navalkele, B. et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin‐tazobactam compared to those on vancomycin and cefepime. Clin. Infect. Dis. 64, 116–123 (2017).
    1. Rutter, W.C. , Cox, J.N. , Martin, C.A. , Burgess, D.R. & Burgess, D.S. Nephrotoxicity during vancomycin therapy in combination with piperacillin‐tazobactam or cefepime. Antimicrob. Agents Chemother. 61 (2017).
    1. Lodise, T.P. , Patel, N. , Lomaestro, B.M. , Rodvold, K.A. & Drusano, G.L. Relationship between initial vancomycin concentration‐time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49, 507–514 (2009).
    1. Pritchard, L. et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am. J. Med. 123, 1143–1149 (2010).
    1. Cano, E.L. et al. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT‐HAP database. Clin. Ther. 34, 149–157 (2012).
    1. Kullar, R. , Davis, S.L. , Levine, D.P. & Rybak, M.J. Impact of vancomycin exposure on outcomes in patients with methicillin‐resistant staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52, 975–981 (2011).
    1. Belen, C. , Budhiraja, P. , Bracamonte, E. & Popovtzer, M. Biopsy‐proven acute tubular necrosis associated with vancomycin in an adult patient. Ren. Fail. 34, 502–505 (2012).
    1. Hsu, S.I. Biopsy‐proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 21, 1233–1239 (2001).
    1. Katikaneni, M. , Lwin, L. , Villanueva, H. & Yoo, J. Acute kidney injury associated with vancomycin when laxity leads to injury and findings on kidney biopsy. Am. J. Ther. 23, e1064–1067 (2016).
    1. Blumenthal, K.G. , Patil, S.U. & Long, A.A. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (dress) syndrome. Allergy Asthma Proc. 33, 165–171 (2012).
    1. Rosini, J.M. et al. High single‐dose vancomycin loading is not associated with increased nephrotoxicity in emergency department sepsis patients. Acad. Emerg. Med. 23, 744–746 (2016).
    1. Rosini, J.M. et al. A randomized trial of loading vancomycin in the emergency department. Ann. Pharmacother. 49, 6–13 (2015).
    1. Lodise, T.P. , Lomaestro, B. , Graves, J. & Drusano, G.L. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother. 52, 1330–1336 (2008).
    1. Chavada, R. , Ghosh, N. , Sandaradura, I. , Maley, M. & Van Hal, S.J. Towards individualised vancomycin dosing in methicillin‐resistant staphylococcus aureus bacteraemia: establishment of an AUC0‐24 threshold for nephrotoxicity. Antimicrob. Agents Chemother. 2017. doi: AAC.02535-16 [pii] [Epub ahead of print].
    1. Wunderink, R.G. et al. Linezolid in methicillin‐resistant staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin. Infect. Dis. 54, 621–629 (2012).
    1. Prabaker, K.K. , Tran, T.P. , Pratummas, T. , Goetz, M.B. & Graber, C.J. Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp. Med. 7, 91–97 (2012).
    1. Meaney, C.J. , Hynicka, L.M. & Tsoukleris, M.G. Vancomycin‐associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy 34, 653–661 (2014).
    1. Hidayat, L.K. , Hsu, D.I. , Quist, R. , Shriner, K.A. & Wong‐Beringer, A. High‐dose vancomycin therapy for methicillin‐resistant staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166, 2138–2144 (2006).
    1. Bosso, J.A. et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob. Agents Chemother. 55, 5475–5479 (2011).
    1. Hall, R.G. et al. Empiric guideline‐recommended weight‐based vancomycin dosing and nephrotoxicity rates in patients with methicillin‐resistant staphylococcus aureus bacteremia: a retrospective cohort study. BMC Pharmacol Toxicol. 14, 12 (2013).
    1. Hanrahan, T.P. et al. Vancomycin‐associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit. Care Med. 42, 2527–2536 (2014).
    1. Waineo, M.F. , Kuhn, T.C. & Brown, D.L. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion. J. Clin. Pharm. Ther. 40, 259–265 (2015).
    1. Cataldo, M.A. , Tacconelli, E. , Grilli, E. , Pea, F. & Petrosillo, N. Continuous versus intermittent infusion of vancomycin for the treatment of gram‐positive infections: systematic review and meta‐analysis. J. Antimicrob. Chemother. 67, 17–24 (2012).
    1. Hanrahan, T. , Whitehouse, T. , Lipman, J. & Roberts, J.A. Vancomycin‐associated nephrotoxicity: a meta‐analysis of administration by continuous versus intermittent infusion. Int. J. Antimicrob. Agents. 46, 249–253 (2015).
    1. Hao, J. , Chen, H. & Zhou, J. Continuous versus intermittent infusion of vancomycin in adult patients: a systematic review and meta‐analysis. Int. J. Antimicrob. Agents. 47, 28–35 (2016).
    1. Grace, E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J. Antimicrob. Chemother. 67, 1305–1310 (2012).
    1. Richardson, J. , Scheetz, M. & O'Donnell, E.P. The association of elevated trough serum vancomycin concentrations with obesity. J. Infect. Chemother. 21, 507–511 (2015).
    1. Arbeit, R.D. et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin‐structure infections. Clin. Infect. Dis. 38, 1673–1681 (2004).
    1. Grosse, E.J.E. et al. The efficacy and safety of tigecycline in the treatment of skin and skin‐structure infections: results of 2 double‐blind phase 3 comparison studies with vancomycin‐aztreonam. Clin. Infect. Dis. 41, S341–S353 (2005).
    1. Davies, S.W. , Guidry, C.A. , Petroze, R.T. , Hranjec, T. & Sawyer, R.G. Vancomycin and nephrotoxicity: just another myth? J. Trauma Acute Care Surg. 75, 830–835 (2013).
    1. Wood, C.A. , Kohlhepp, S.J. , Kohnen, P.W. , Houghton, D.C. & Gilbert, D.N. Vancomycin enhancement of experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother. 30, 20–24 (1986).
    1. Farber, B.F. & Moellering, R.C. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob. Agents Chemother. 23, 138–141 (1983).
    1. Sorrell, T.C. & Collignon, P.J. A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicrob. Chemother. 16, 235–241 (1985).
    1. Rybak, M.J. , Albrecht, L.M. , Boike, S.C. & Chandrasekar, P.H. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 25, 679–687 (1990).
    1. Hanrahan, T.P. et al. Factors associated with vancomycin nephrotoxicity in the critically ill. Anaesth. Intens. Care 43, 594–599 (2015).
    1. Goetz, M.B. & Sayers, J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J. Antimicrob. Chemother. 32, 325–334 (1993).
    1. Gomes, D.M. et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin‐tazobactam or cefepime. Pharmacotherapy 34, 662–669 (2014).
    1. Kim, T. et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res. Notes 8, 579 (2015).
    1. Fodero, K.E. et al. Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin. Clin. Ther. 38, 494–502 (2016).
    1. Moenster, R.P. et al. Acute renal failure associated with vancomycin and β‐lactams for the treatment of osteomyelitis in diabetics: piperacillin‐tazobactam as compared with cefepime. Clin. Microbiol. Infect. 20, O384–O389 (2014).
    1. Hammond, D.A. , Smith, M.N. , Painter, J.T. , Meena, N.K. & Lusardi, K. Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin‐tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy 36, 463–471 (2016).
    1. Giuliano, C. , Patel, C.R. & Kale‐Pradhan, P.B. Is the combination of piperacillin‐tazobactam and vancomycin associated with development of acute kidney injury? a meta‐analysis. Pharmacotherapy 2017. doi: [Epub ahead of print].
    1. Hammond, D.A. et al. Systematic review and meta‐analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin. Infect. Dis. 2016. doi: ciw811 [pii] [Epub ahead of print].
    1. Jensen, J.S. et al. Kidney failure related to broad‐spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open 2, (2012).
    1. Karino, S. et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin‐tazobactam: opportunities for antimicrobial stewardship. Antimicrob. Agents Chemother. 60, 3743–3750 (2016).

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner